Neurol. praxi. 2011;12(2):135-137

Old and new diagnostic criteria for Alzheimer’s disease in the conditions of the Czech Republic

doc.MUDr.Roman Jirák, CSc.
Psychiatrická klinika, 1. LF UK, Praha

In spite of the fact, that we don´t correctly know the ethiopatogenesis of Alzheimer´s disease and thus we are unable to cure this disease, it

is important timely diagnostics. At the case of the determination of correct diagnose we are able to start therapy in time. This therapy is able

to remove the advanced stadia of the disease, to extend the mild stadia of the disease, to improve of the quality of live of the patiens. For

the diagnostics there are still used McKhann´s kriteria, going out of the clinical picture of the disease. In 2007 there were elaborated by prof.

Dubois et al. the new criterias, based on the determination of the protein triplet (tau, phospho-tau and beta-amyloid 42) in cerebrospinal

fluid, on the MRI scan (volumetry of medial temporal areas and the temporal corners of side brain chambers), on the determination of the

cerebral blood flow in the temporal and parietal lobes by positron emission tomography and on the determination of beta-amyloid deposits

in the brain by positron emission tomography. Important biomarker of Alzheimer´s disease is early disturbance of episodic memory. In

present time there are investigated the new diagnostic methods, for instance the determination of some biomarkers from the blood.

Keywords: Alzheimer´s disease, dementia, diagnostic criterias, differential diagnostics

Published: June 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jirák R. Old and new diagnostic criteria for Alzheimer’s disease in the conditions of the Czech Republic. Neurol. praxi. 2011;12(2):135-137.
Download citation

References

  1. Blennow K, Hampel H, Werner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010; 6(3): 131-144. Go to original source... Go to PubMed...
  2. Cummings JL. Biomarkers in Alzheimer´s Disease - Perspectives for the future. US Neurology 2010; 6(1): 23-27. Go to original source...
  3. Dubois B, Feldman HH, Jacova C, DeKosky ST, BarbergerGateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O´Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research kriteria for the diagnosis of Alzheimer´s disease: revising the NINCDSADRDA kriteria. Lancet Neurol. 2007; 6(8): 734-746. Go to original source... Go to PubMed...
  4. Hampel H, Bürger K, Teipel SJ, Bokde ALW, Zetterberg H, Blennow Kai. Core candidate neurochemical and imaging biomarkers of Alzheimer´s disease. Alzheimer´s & Dementia, 2008; 4(1): 38-48. Go to original source... Go to PubMed...
  5. Hort J. Guidelines pro terapii Alzheimerovy nemoci v podmínkách ČR a terapeutické novinky na obzoru. www.kognice.cz/kurz Brno 2009.
  6. Humpel Ch. Identifying and validating biomarkers for Alzheimer´s disease. Trends in Biotechnology, 2010; 29(1): 26-32. Go to original source... Go to PubMed...
  7. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer´s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer´s Disease. Neurology 1984; 34(7): 939-944. Go to original source... Go to PubMed...
  8. Sperling R, Johnson K. Pro: Can biomarkers be gold standards in Alzheimer´s disease? Alzheimer´s Research & Therapy 2010; 2: 17-19. Go to original source... Go to PubMed...
  9. Vanderstichele H, De Meyer G, Shapiro F, Engelborghs S, De Deyn PP, Shaw LM. And Trojanowski J.Q.: Alzheimer´s disease biomarkers: From koncept to utility. In: Galimberti D, Scrapini E. (eds).: Biomarkers for early diagnosis of Alzheimer´s disease. Nova Science Publisher, Inc. 2008: 81-122.




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.